Skip to content

Study · Randomized controlled trial · n = 463 · 2017

6 results

Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.

Mason M, Richaud P, Bosnyak Z, Malmberg A, Neijber A

Lower urinary tract symptoms7 Oct 2015Cited by 12 (Europe PMC)

PMID28394498 (opens in a new tab)DOI10.1111/luts.12114 (opens in a new tab)PepBankPUB-28394498
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, degarelix reduced IPSS more than goserelin plus bicalutamide at week 12 (adjusted difference -1.24, P = 0.03).

    In plain wordsIn prostate cancer patients, degarelix reduced urinary symptom scores more than goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    DecreaseIPSS at week 12
    Study

    n = 463

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Adjusted IPSS difference at week 12
    −1.24 IPSS points
    degarelix vs goserelin plus bicalutamide
    95% CI
    −2.33 to −0.14 IPSS points
    adjusted IPSS difference
    P
    0.03
    adjusted IPSS difference

    Source sentences

    Summary
    Patients receiving degarelix had significantly greater decreases in IPSS vs. goserelin at week 12 (adjusted difference: -1.24; 95% CI -2.33 to -0.14, P = 0.03).
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, early LUTS relief favored degarelix over goserelin plus bicalutamide (OR 2.03, P = 0.02).

    In plain wordsIn prostate cancer patients, early urinary symptom relief favored degarelix over goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    IncreaseLUTS relief at week 4
    Study

    n = 463

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Odds ratio for LUTS relief at week 4
    2.03 OR
    week 4
    95% CI
    1.14 to 3.6 OR
    week 4
    P
    0.02
    week 4

    Source sentences

    Summary
    A twofold higher OR for early (week 4) LUTS relief was seen with degarelix vs. goserelin (OR 2.03; 95% CI 1.14-3.60, P = 0.02).
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients, total prostate volume did not differ between degarelix and goserelin plus bicalutamide.

    In plain wordsIn prostate cancer patients, prostate volume did not differ between degarelix and goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    No significant changeTotal prostate volume
    Study

    n = 463

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No difference in total prostate volume or urinary tract infection-related adverse events (2%) was seen between treatment groups.
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.
  4. 04HumanRandomized controlled trialSafety outcome

    In prostate cancer patients, urinary tract infection-related adverse events (2%) did not differ between degarelix and goserelin plus bicalutamide.

    In plain wordsIn prostate cancer patients, urinary infection-related adverse events did not differ between degarelix and goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    No significant changeUrinary tract infection-related adverse events
    Study

    n = 463

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Urinary tract infection-related adverse events
    2%
    reported for the treatment groups

    Source sentences

    Summary
    No difference in total prostate volume or urinary tract infection-related adverse events (2%) was seen between treatment groups.
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In prostate cancer patients with baseline IPSS ≥13, LUTS relief favored degarelix over goserelin plus bicalutamide (OR 2.31).

    In plain wordsIn prostate cancer patients with moderate-to-severe urinary symptoms, relief favored degarelix over goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    IncreaseLUTS relief with moderate-to-severe LUTS
    Study

    n: not reported in source

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Odds ratio for clinically relevant LUTS relief
    2.31 OR
    moderate-to-severe LUTS (baseline IPSS >=13)
    95% CI
    1.19 to 4.47 OR
    moderate-to-severe LUTS
    P
    0.01
    moderate-to-severe LUTS

    Source sentences

    Summary
    Clinically relevant LUTS relief with degarelix was especially pronounced in patients with moderate-to-severe LUTS (baseline IPSS ≥13) (odds ratio; OR 2.31; 95% CI 1.19-4.47, P = 0.01) and advanced PCa (OR 2.36; 95% CI 1.10-5.04, P = 0.03).
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In advanced prostate cancer, LUTS relief favored degarelix over goserelin plus bicalutamide (OR 2.36, P = 0.03).

    In plain wordsIn advanced prostate cancer, urinary symptom relief favored degarelix over goserelin plus bicalutamide.

    Peptide
    Degarelix
    Outcome
    IncreaseLUTS relief with advanced prostate cancer
    Study

    n: not reported in source

    Comparator
    Goserelin plus bicalutamide
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    240/80 mg once monthly · 12 weeksAs given in this study (human).

    Measurements

    Odds ratio for clinically relevant LUTS relief
    2.36 OR
    advanced PCa
    95% CI
    1.1 to 5.04 OR
    advanced PCa
    P
    0.03
    advanced PCa

    Source sentences

    Summary
    Clinically relevant LUTS relief with degarelix was especially pronounced in patients with moderate-to-severe LUTS (baseline IPSS ≥13) (odds ratio; OR 2.31; 95% CI 1.19-4.47, P = 0.01) and advanced PCa (OR 2.36; 95% CI 1.10-5.04, P = 0.03).
    1 context sentence
    Summary · context
    Data were pooled from three Phase 3, randomized clinical trials of once-monthly treatment for 12 weeks with degarelix (240/80 mg; n = 289) or goserelin (3.6 mg) plus bicalutamide (50 mg; n = 174) for initial flare protection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.